WHO. Hepatitis B: WHO; 2018 [cited 2018 10-08-2018]. Available from: http://www.who.int/mediacentre/factsheets/fs204/es/.
O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl Trop Dis. 2017;11(10):e0005842.
Article
Google Scholar
WHO. Global hepatitis report, 2017. In: WHO; 2017.
Google Scholar
Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, et al. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections Infection, genetics and evolution. Journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2013;16:355–61.
Article
CAS
Google Scholar
Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. time for an individualised approach? J Hepatol. 2017;67(6):1281–97.
Article
Google Scholar
Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut. 2008;57(12):1713–20.
Article
CAS
Google Scholar
Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat. 1999;6(4):299–304.
Article
CAS
Google Scholar
Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes a, B, and C. J Gastroenterol. 2002;37(1):35–9.
Article
Google Scholar
Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype a and treatment in Japan. J Med Virol. 2005;76(1):33–9.
Article
Google Scholar
Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122(7):1756–62.
Article
CAS
Google Scholar
Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes a, B, C, D, and F. Gastroenterology. 2007;133(5):1452–7.
Article
CAS
Google Scholar
Westland C, Delaney WT, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107–16.
Article
CAS
Google Scholar
Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265–72.
Article
CAS
Google Scholar
Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol. 2002;40(1):22–5.
Article
Google Scholar
Yousif M, Mudawi H, Bakhiet S, Glebe D, Kramvis A. Molecular characterization of hepatitis B virus in liver disease patients and asymptomatic carriers of the virus in Sudan. BMC Infect Dis. 2013;13:328.
Article
CAS
Google Scholar
Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43(3):411–7.
Article
CAS
Google Scholar
Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002;123(6):1848–56.
Article
Google Scholar
Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5–11.
Article
CAS
Google Scholar
Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(16):1134–43.
Article
CAS
Google Scholar
Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype a in bantu-speaking sub-saharan Africans. J Med Virol. 2005;75(4):513–21.
Article
CAS
Google Scholar
Lampertico PVM, Soffredini R. Entecavir monotherapy for nuc-na€ıve chronic hepatitis B patients from field practice: high efficacy and favorable 0safety profile over 3 year. Hepatology. 2011;54:A1436.
Google Scholar
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57(3):508–14.
Article
CAS
Google Scholar
Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62(5):760–5.
Article
CAS
Google Scholar
Kim JH, Jung SW, Byun SS, Shin JW, Park BR, Kim MH, et al. Efficacy and safety of tenofovir in nucleos(t)ide-naive patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm. 2015;37(6):1228–34.
Article
CAS
Google Scholar
Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, et al. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol. 2017;9(1):48–56.
Article
Google Scholar
Malagnino V, Salpini R, Maffongelli G, Battisti A, Fabeni L, Piermatteo L, et al. High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. PLoS One. 2018;13(3):e0195045.
Article
Google Scholar
Archampong TN, Boyce CL, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, et al. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients. Antivir Ther. 2017;22(1):13–20.
Article
Google Scholar
Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholie SP, et al. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from sub-Saharan Africa. J Gastroenterol Hepatol. 2016;31(3):634–44.
Article
CAS
Google Scholar
Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, et al. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from cote d'Ivoire. Antivir Ther. 2015;20(6):643–54.
Article
CAS
Google Scholar
Honge BL, Jespersen S, Medina C, Te Dda S, da Silva ZJ, Lewin S, et al. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One. 2014;9(6):e99971.
Article
Google Scholar
De Francesco MA, Gargiulo F, Spinetti A, Zaltron S, Giagulli C, Caccuri F, et al. Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine. The new microbiologica. 2015;38(1):29–37.
CAS
PubMed
Google Scholar
Boglione L, Cardellino CS, De Nicolo A, Cariti G, Di Perri G, D'Avolio A. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype a, D and E. J Med Virol. 2014;86(11):1845–50.
Article
CAS
Google Scholar
Boglione L, Cariti G, Ghisetti V, Burdino E, Di Perri G. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis. J Med Virol. 2018;90(6):1047–52.
Article
CAS
Google Scholar
Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. The Journal of infection. 2014;69(1):81–7.
Article
Google Scholar
Erhardt A, Gobel T, Ludwig A, Lau GK, Marcellin P, van Bommel F, et al. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol. 2009;81(10):1716–20.
Article
CAS
Google Scholar
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
Article
Google Scholar
Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Minichini C, et al. Hepatitis B virus infection in undocumented immigrants and refugees in southern Italy: demographic, virological. and clinical features Infectious diseases of poverty. 2017;6(1):33.
Article
Google Scholar
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.
Article
CAS
Google Scholar
Cuenca-Gomez JA, Salas-Coronas J, Soriano-Perez MJ, Vazquez-Villegas J, Lozano-Serrano AB, Cabezas-Fernandez MT. Viral hepatitis and immigration: a challenge for the healthcare system. Revista clinica espanola. 2016;216(5):248–52.
Article
CAS
Google Scholar
European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227–42.
Article
Google Scholar
European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.
Article
Google Scholar
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
Article
Google Scholar
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology. 1996;24(2):289–93.
CAS
Google Scholar
Botha JF, Ritchie MJ, Dusheiko GM, Mouton HW, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet. 1984;1(8388):1210–2.
Article
CAS
Google Scholar
Kew MC. Hepatocellular carcinoma in African blacks: recent progress in etiology and pathogenesis. World J Hepatol. 2010;2(2):65–73.
Article
Google Scholar
Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. Journal of infection and public health. 2016;9(4):389–95.
Article
Google Scholar
Marcellin P, Zoulim F, Hezode C, Causse X, Roche B, Truchi R, et al. Effectiveness and safety of Tenofovir Disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;61(10):3072–83.
Article
CAS
Google Scholar
Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010;52(3):441–9.
Article
CAS
Google Scholar
Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, et al. Effectiveness and safety of Tenofovir Disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci. 2016;61(10):3061–71.
Article
CAS
Google Scholar
Ahn HJ, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK. Treatment efficacy and safety of Tenofovir-based therapy in chronic hepatitis B: a real life cohort study in Korea. PLoS One. 2017;12(1):e0170362.
Article
Google Scholar
Pereira CV, Tovo CV, Grossmann TK, Mirenda H, Dal-Pupo BB, Almeida PR, et al. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. Memorias do Instituto Oswaldo Cruz. 2016;111(4):252–7.
Article
CAS
Google Scholar
Buti M, Morillas RM, Prieto M, Diago M, Perez J, Sola R, et al. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2012;24(5):535–42.
Article
CAS
Google Scholar
Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China. J Viral Hepat. 2013;20(11):811–20.
PubMed
Google Scholar
Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Munoz AE, Adrover R, et al. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naive patients in clinical practice. Ann Hepatol. 2014;13(3):327–36.
PubMed
Google Scholar
Liu A, Ha NB, Lin B, Yip B, Trinh HN, Nguyen HA, et al. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. Eur J Gastroenterol Hepatol. 2013;25(3):338–43.
Article
CAS
Google Scholar
Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427–33.
Article
CAS
Google Scholar
Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013;28(1):46–50.
Article
Google Scholar
Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264–71.
Article
CAS
Google Scholar
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther. 2016;43(1):134–44.
Article
CAS
Google Scholar
Pawlowska M, Domagalski K, Smok B, Rajewski P, Wietlicka-Piszcz M, Halota W, et al. Continuous up to 4 years Entecavir treatment of HBV-infected adolescents - a longitudinal study in real life. PLoS One. 2016;11(9):e0163691.
Article
Google Scholar
Carey INH, Joe D. Denovo antiviral therapy with nucleos(t)ide analogues in ‘real-life’ patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy. Hepatology. 2011;54:A1396.
Google Scholar
Baqai SFYD, Gish RG. Profound virologic response in chronic hepatitis B (CHB) patients treated with entecavir (ETV) in HBeAg positive and negative disease. Hepatology. 2009;50(S4):530A.
Google Scholar